Measuring fatigue in SSc: A comparison of the short form-36 vitality subscale and functional assessment of chronic illness therapy-fatigue scale

Rheumatology (United Kingdom)

Volumn 51, Issue 12, 2012, Pages 2177-2185

  Harel, Daphna ^a   Thombs, Brett D ^a,b   Hudson, Marie ^a,b   Baron, Murray ^a,b   Steele, Russell ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

FACIT; Fatigue; Psychometrics; Scleroderma; SF 36 vitality; SSc

Indexed keywords

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SHORT FORM 36; SYSTEMIC SCLEROSIS;

CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 84870337614     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes206     Document Type: Article

References (62)

1. Siebold J. Scleroderma. In: Harris E, Budd R, Firestein G, Genovese M, Sergent J, Ruddy S, eds. Kelley's textbook of rheumatology. 7th edn. Philadelphia: Elsevier, 2005.
2. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008;37: 223-35.
3. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
4. Bernatsky S, Hudson M, Panopalis P et al. The cost of systemic sclerosis. Arthritis Rheum 2009;61:119-23.
5. Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
6. Thombs B, Taillefer S, Hudson M, Baron M. Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum 2007;57: 1089-97.
7. Hudson M, Thombs BD, Steele R et al. Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009;61:1112-20.
8. Swain MG. Fatigue in chronic disease. Clin Sci (Lond) 2000;99:1-8.
9. Bassel M, Hudson M, Taillefer SS et al. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian national survey. Rheumatology (Oxford) 2011;50:762-67.
10. Van Lankveld WG, Vonk MC, Teunissen H, van den Hoogen FH. Appearance self-esteem in systemic sclerosis: subjective experience of skin deformity and its relationship with physician-assessed skin involvement, disease status and psychological variables. Rheumatology 2007;46:872-76.
11. Thombs BD, Bassel M, McGuire L et al. A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples. Rheumatology 2008;47:1559-63.
12. Hudson M, Steele R, Lu Y et al. Work disability in systemic sclerosis. J Rheumatol 2009;36:2481-6.
13. Sandqvist G, Eklund M. Daily occupations-performance, satisfaction and time use, and relations with well-being in women with limited systemic sclerosis. Disabil Rehabil 2008;30:27-35.
14. Sandqvist G, Scheja A, Eklund M. Working ability in relation to disease severity, everyday occupations and well-being in women with limited systemic sclerosis. Rheumatology 2008;47:1708-11.
15. Sandusky SB, McGuire L, Smith MT et al. Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology 2009;48:165-9.
16. Thombs BD, Hudson M, Bassel M et al. Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients. Arthritis Rheum 2009;61:966-73.
17. Ware JE. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;473-83.
18. Belza BL, Henke C, Yelin E, Epstein W, Gilliss C. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993;42:93-9.
19. Ibn Yacoub Y, Amine B, Bensabbah R, Hajjaj-Hassouni N. Assessment of fatigue and its relationships with disease-related parameters in patients with systemic sclerosis. Clin Rheumatol 2012;31:655-60.
20. Sandqvist G, Archenholtz B, Scheja A, Hesselstrand R. The Swedish version of the Multidimensional Assessment of Fatigue (MAF) in systemic sclerosis: reproducibility and correlations to other fatigue instruments. Scand J Rheumatol 2011;40:493-94.
21. Rannou F, Poiraudeau S, Berenzne A et al. Assessing disability and quality of life in systemic sclerosis: Construct Validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007;57: 94-102.
22. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Evanston: Evanston Northwestern Healthcare and Northwestern University. Version 4, 1997.
23. Cella D, Yount S, Sorensen M et al. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-9.
24. Furst DE, Clements PJ, Steen VD et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25: 84-8.
25. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
26. Symmons DP. Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol 1995;9: 267-85.
27. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73.
28. Medsger TA Jr, Silman AJ, Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
29. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003;21(3 Suppl 29): S39-41.
30. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 1988;31:817-25.
31. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156-63.
32. Clements PJ, Seibold J, Furst DE et al. High-dose versus low-dose penicillamine in early diffuse systemic sclerosis trial: Lessons Learned. Semin Arthritis Rheum 2004;33: 249-63.
33. Hudson M, Impens A, Baron M et al. Discordance between patient and physician assessments of disease severity in systemic sclerosis. J Rheumatol 2010;37: 2307-12.
34. Fan X, Pope J, Baron M. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int 2010;30:1205-10.
35. Ware JE, Kosinski M, Dewey JE. How to score Version Two of the SF-36- Health Survey. Lincoln, RI: QualityMetric Inc., 2000.
36. Dauphinee SW, Gauthier L, Gandek B, Magnan L, Pierre U. Readying a US measure of health status, the SF-36, for use in Canada. Clin Invest Med 1997;20: 224-38.
37. Yellen SB, Cella D, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manag 1997;13: 63-74.
38. Signorovitch J, Brainsky A, Grotzinger K. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Qual Life Res 2011; 20:1737-44.
39. Hudson M, Steele R, Lu Y et al. Clinical correlates of self-reported physical health status in systemic sclerosis. J Rheumatol 2009;36:1226-9.
40. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patientgenerated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40: 1984-91.
41. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
42. Van Tubergen A, Debats I, Ryser L et al. Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum 2002; 47:242-8.
43. Ferraz MB, Quaresma MR, Aquino LR, et al. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 1990;17: 1022-4.
44. Johnson S, Hawker G, Davis A. The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthrit Care Res 2005;52:256-62.
45. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
46. Radloff LS, Locke BZ. Community surveys of psychiatric disorders. In: Weisman NM, Myers JK, Ross CE, eds. The Community Mental Health Assessment Surveys and the CES-D scale. New Brunswick: Rutgers University, 1986.
47. Thombs BD, Hudson M, Schieir O, Taillefer SS, Baron M. Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. Arthritis Rheum 2008;59:438-43.
48. Efron B, Tibshirani R. An introduction to the bootstrap. Boca Raton: Chapman & Hall/CRC, 1993.
49. Marsh H, Hocevar D. Application of confirmatory factor analysis to the study of self-concept: first- and higher order factor models and their invariance across groups. Psy Bull 1985;562-82.
50. Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc 1995;90:773-95.
51. Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4.
52. Browne MW, Cudeck R. Alternative ways of assessing model fit. Sociol Meth Reas 1992;21:230-58.
53. Masters GN. A Rasch model for partial credit scoring. Psychometrika 1982;47:149-74.
54. Molenaar IW, Sijtsma K. User's Manual MSP5 for Windows. Groningen: IEC ProGAMMA The Netherlands, 2000.
55. Van der Ark L. A. Mokken (version 2.6): an R package for Mokken scale analysis [computer software] 2011. http://cran.r-project.org/web/packages/mokken/index.html (15 December 2011, date last accessed).
56. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2010.
57. Canty A, Ripley B. Boot: Bootstrap R (S-Plus) Functions. R package version 1.2-43; 2010.
58. Davison AC, Hinkley DV. Bootstrap methods and their applications. Cambridge: Cambridge University Press, 1997.
59. Rizopoulus D. ltm: An R package for latent variable modeling and item response theory analyses. J Stat Softw 2006;17:1-25.
60. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-9.
61. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-54.
62. Singh M, Clements P, Furst D, Maranian P, Khanna D. Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study. Arthrit Care Res 2012;64:176-83.